Related references
Note: Only part of the references are listed.Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes
Per Lundkvist et al.
DIABETES OBESITY & METABOLISM (2017)
Combination therapy for obesity
John P. H. Wilding
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes
Robert S. Busch et al.
POSTGRADUATE MEDICINE (2017)
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year
Per Lundkvist et al.
DIABETES OBESITY & METABOLISM (2017)
Hyperinsulinemia: a Cause of Obesity?
Karel A. Erion et al.
CURRENT OBESITY REPORTS (2017)
Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial
Priscilla Hollander et al.
DIABETES CARE (2017)
Effect of exenatide on postprandial glucose fluxes, lipolysis, and β-cell function in non-diabetic, morbidly obese patients
Stefania Camastra et al.
DIABETES OBESITY & METABOLISM (2017)
Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments A Systematic Review and Network Meta-analysis
Francesco Zaccardi et al.
ANNALS OF INTERNAL MEDICINE (2016)
Baseline characteristics associated with different BMI trajectories in weight loss trials: a case for better targeting of interventions
M. Batterham et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2016)
Food cue reactivity and craving predict eating and weight gain: a meta-analytic review
Rebecca G. Boswell et al.
OBESITY REVIEWS (2016)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
Sunder Mudaliar et al.
DIABETES CARE (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study
Robert R. Henry et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2016)
Exenatide Improves Both Hepatic and Adipose Tissue Insulin Resistance: A Dynamic Positron Emission Tomography Study
Amalia Gastaldelli et al.
HEPATOLOGY (2016)
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Matthew J. Armstrong et al.
JOURNAL OF HEPATOLOGY (2016)
How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake
David Polidori et al.
Obesity (2016)
Patients with obesity-related comorbidities have higher disability compared with those without obesity-related comorbidities: results from a cross-sectional study
Anna Sirtori et al.
INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH (2016)
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
Deepson S Shyangdan et al.
BMJ Open (2016)
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
Juan P. Frias et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition
Giulia Ferrannini et al.
DIABETES CARE (2015)
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition
Anne L. Peters et al.
DIABETES CARE (2015)
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data
S. Del Prato et al.
DIABETES OBESITY & METABOLISM (2015)
Physiological adaptations to weight loss and factors favouring weight regain
F. L. Greenway
INTERNATIONAL JOURNAL OF OBESITY (2015)
Effects of weight regain following intentional weight loss on glucoregulatory function in overweight and obese adults with pre-diabetes
Kristen M. Beavers et al.
OBESITY RESEARCH & CLINICAL PRACTICE (2015)
Comorbidity associated with obesity in a large population: The APNA study
Elena Martin-Rodriguez et al.
OBESITY RESEARCH & CLINICAL PRACTICE (2015)
Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Andre J. Scheen
DRUGS (2015)
Predicting adult weight change in the real world: a systematic review and meta-analysis accounting for compensatory changes in energy intake or expenditure
E. J. Dhurandhar et al.
INTERNATIONAL JOURNAL OF OBESITY (2015)
The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
Jessica E. Potts et al.
PLOS ONE (2015)
Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis
Elizabeth S. Mearns et al.
PLOS ONE (2015)
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
J. Bolinder et al.
DIABETES OBESITY & METABOLISM (2014)
Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin
Sunder Mudaliar et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2014)
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
L. van Bloemendaal et al.
JOURNAL OF ENDOCRINOLOGY (2014)
Impact of Weight Regain on Metabolic Disease Risk: A Review of Human Trials
Cynthia M. Kroeger et al.
JOURNAL OF OBESITY (2014)
Relation Between Serum Free Fatty Acids and Adiposity, Insulin Resistance, and Cardiovascular Risk Factors From Adolescence to Adulthood
Brigitte I. Frohnert et al.
DIABETES (2013)
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
Ralph A. DeFronzo et al.
DIABETES CARE (2013)
Cardiometabolic Risk After Weight Loss and Subsequent Weight Regain in Overweight and Obese Postmenopausal Women
Daniel P. Beavers et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2013)
Preoperative Predictors of Weight Loss Following Bariatric Surgery: Systematic Review
Masha Livhits et al.
OBESITY SURGERY (2012)
Body Weight, Not Insulin Sensitivity or Secretion, May Predict Spontaneous Weight Changes in Nondiabetic and Prediabetic Subjects The RISC Study
Eleni Rebelos et al.
DIABETES (2011)
Obesity 3 Quantification of the effect of energy imbalance on bodyweight
Kevin D. Hall et al.
LANCET (2011)
Gene Variants of TCF7L2 Influence Weight Loss and Body Composition During Lifestyle Intervention in a Population at Risk for Type 2 Diabetes
Axel Haupt et al.
DIABETES (2010)
Gene Variants in the Novel Type 2 Diabetes Loci CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B Affect Different Aspects of Pancreatic beta-Cell Function
Annemarie M. Simonis-Bik et al.
DIABETES (2010)
Regularization Paths for Generalized Linear Models via Coordinate Descent
Jerome Friedman et al.
JOURNAL OF STATISTICAL SOFTWARE (2010)
A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion
S. A. Schaefer et al.
DIABETOLOGIA (2009)
Common variants in WFS1 confer risk of type 2 diabetes
Manjinder S. Sandhu et al.
NATURE GENETICS (2007)
WFS1 protein modulates the free Ca2+ concentration in the endoplasmic reticulum
Daisuke Takei et al.
FEBS LETTERS (2006)
WFS1-deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway specifically in pancreatic β-cells
T Yamada et al.
HUMAN MOLECULAR GENETICS (2006)
Mice conditionally lacking the Wolfram gene in pancreatic islet beta cells exhibit diabetes as a result of enhanced endoplasmic reticulum stress and apoptosis
AC Riggs et al.
DIABETOLOGIA (2005)
Bayesian model averaging: development of an improved multi-class, gene selection and classification tool for microarray data
KY Yeung et al.
BIOINFORMATICS (2005)
Share Paper
